Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration

Journal of Periodontology

Volumn 82, Issue 11, 2011, Pages 1582-1586

  Lai, Pin Chuang ^a   Ho, Weiting ^a   Jain, Nidhi ^a   Walters, John D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Anti infective agents; Periodontitis; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; GINGIVITIS; HUMAN; MALE; METABOLISM; REFERENCE VALUE; SERUM;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; FEMALE; GINGIVAL CREVICULAR FLUID; HUMANS; MALE; REFERENCE VALUES; SERUM;

EID: 80655129370     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2011.110012     Document Type: Article

References (36)

1. Christersson LA, Albini B, Zambon JJ, Wikesjö UM, Genco RJ. Tissue localization of Actinobacillus actinomycetemcomitans in human periodontitis. I. Light, immunofluorescence and electron microscopic studies. J Periodontol 1987;58:529-539.
2. Duncan MJ, Nakao S, Skobe Z, Xie H. Interactions of Porphyromonas gingivalis with epithelial cells. Infect Immun 1993;61:2260-2265. (Pubitemid 23145947)
3. Lamont RJ, Chan A, Belton CM, Izutsu KT, Vasel D, Weinberg A. Porphyromonas gingivalis invasion of gingival epithelial cells. Infect Immun 1995;63:3878-3885.
4. Dorn BR, Leung KL, Progulske-Fox A. Invasion of human oral epithelial cells by Prevotella intermedia. Infect Immun 1998;66:6054-6057. (Pubitemid 28531877)
5. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol 2003;8:115-181.
6. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992;36:1241-1243.
7. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993;8:325-326.
8. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 1999;43:2801-2805. (Pubitemid 29519570)
9. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996;23:998-1003. (Pubitemid 126732071)
10. Chou CH, Walters JD. Clarithromycin transport by gingival fibroblasts and epithelial cells. J Dent Res 2008;87:777-781.
11. Schroeder HE, Listgarten MA. The gingival tissues: The architecture of periodontal protection. Periodontol 2000 1997;13:91-120. (Pubitemid 127579973)
12. Burrell RC, Walters JD. Distribution of systemic clarithromycin to gingiva. J Periodontol 2008;79:1712-1718.
13. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966. (Pubitemid 29453273)
14. Gomi K, Yashima A, Iino F, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 2007;78:918-923.
15. Conway TB, Beck FM, Walters JD. Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites. J Periodontol 2000;71:1448-1452.
16. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963; 21:533-551.
17. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
18. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl. A):73-82. (Pubitemid 20043952)
19. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34:1056-1060. (Pubitemid 20177355)
20. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282. (Pubitemid 19071957)
21. Malizia T, Tejada MR, Ghelardi E, et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997; 68:1206-1209. (Pubitemid 28041650)
22. Gordon JM, Walker CB, Murphy JC, Goodson JM, Socransky SS. Tetracycline: Levels achievable in gingival crevice fluid and in vitro effect on subgingival organisms. Part I. Concentrations in crevicular fluid after repeated doses. J Periodontol 1981;52:609-612. (Pubitemid 12250795)
23. Pascale D, Gordon J, Lamster I, Mann P, Seiger M, Arndt W. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986;13:841-844. (Pubitemid 17198343)
24. Lavda M, Clausnitzer CE, Walters JD. Distribution of systemic ciprofloxacin and doxycycline to gingiva and gingival crevicular fluid. J Periodontol 2004;75:1663-1667. (Pubitemid 40260018)
25. Jain R, Danziger LH. The macrolide antibiotics: A pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004;10:3045-3053. (Pubitemid 39242900)
26. Van Bambeke F, Tulkens PM. Macrolides: Pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001;18(Suppl. 1):S17-S23. (Pubitemid 33713498)
27. Tamura A, Ara T, Imamura Y, Fujii T, Wang PL. The effects of antibiotics on in vitro biofilm model of periodontal disease. Eur J Med Res 2008;13:439-445.
28. Nagino K, Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect 1997;3:432-439. (Pubitemid 27379981)
29. Haas AN, de Castro GD, Moreno T, et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. J Clin Periodontol 2008;35:696-704.
30. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: Clinical results. J Clin Periodontol 2002;29:54-61. (Pubitemid 41697735)
31. Mascarenhas P, Gapski R, Al-Shammari K, et al. Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers. J Periodontol 2005;76:426-436. (Pubitemid 40668390)
32. Oteo A, Herrera D, Figuero E, O'Connor A, González I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: A pilot study. J Clin Periodontol 2010;37:1005-1015.
33. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008;8:286-291.
34. Ho W, Eubank T, Leblebicioglu B, Marsh C, Walters J. Azithromycin decreases crevicular fluid volume and mediator content. J Dent Res 2010;89:831-835.
35. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006;350:977-982. (Pubitemid 44584188)
36. Griffiths GS. Formation, collection and significance of gingival crevice fluid. Periodontol 2000 2003;31:32-42. (Pubitemid 37487408)